Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Inclusion Criteria: * Subjects with Non-Erosive Gastroesophageal Reflux Disease identifying their main symptom as heartburn. * History of episodes of heartburn for 6 months or longer prior to screening. * History of episodes of heartburn for 4 or more days during the 7 days prior to Day -1 as recorded in the electronic diary. Exclusion Criteria: * Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol or prokinetics throughout the study * Erosive Esophagitis seen on endoscopy during study screening. * Co-existing diseases affecting the esophagus. * Abnormal laboratory values that suggest significant clinical disease. * Known acquired immunodeficiency syndrome (AIDS) * Females pregnant or lactating. * History of Alcohol abuse. * History of Cancer within 3 years prior to screening. * Chronic (\>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors * Use of antacids (except for study supplied Gelusil® ) * Use of drugs with significant anticholinergic effects * Need for continuous anticoagulant (blood thinner) therapy * Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus * History of dilatation of esophageal strictures, other than a Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter) * Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition * History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer * Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason. * Acute upper gastrointestinal (UGI) hemorrhage within 4 weeks of the Screening endoscopy